Kairos Pharma Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

—

EPS

Div Yield, %

—

Shrs. gr., 5y

—

Rev. gr., 5y

Revenues

Net income

CFO

Profile

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.

URL

https://kairospharma.com

IPO date

Sep 16, 2024

Employees

Domiciled in

Incorporated in

Valuation

No data to show